All In Biotech

Drug Trial Radar · NCT05413655

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 As Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 8, 2022

Primary completion

Dec 31, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
ExcelsiorIndustry
Sponsor type
Industry
Collaborators
Formosa Biomedical Technology Corp.
First posted
Jun 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

  • EX039Drug

    The dosage form of EX039 is the capsule for oral use

  • PlaceboDrug

    The dosage form of Placebo is the capsule for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Alzheimer's Disease Assessment Scale-cognitiveTime frame: Week 28
  2. Change in Clinical Dementia Rating-Sum of BoxesTime frame: Week 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.